Frances A. Shepherd

81.3k total citations · 20 hit papers
671 papers, 49.5k citations indexed

About

Frances A. Shepherd is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Frances A. Shepherd has authored 671 papers receiving a total of 49.5k indexed citations (citations by other indexed papers that have themselves been cited), including 468 papers in Pulmonary and Respiratory Medicine, 443 papers in Oncology and 111 papers in Cancer Research. Recurrent topics in Frances A. Shepherd's work include Lung Cancer Treatments and Mutations (431 papers), Lung Cancer Research Studies (220 papers) and Lung Cancer Diagnosis and Treatment (174 papers). Frances A. Shepherd is often cited by papers focused on Lung Cancer Treatments and Mutations (431 papers), Lung Cancer Research Studies (220 papers) and Lung Cancer Diagnosis and Treatment (174 papers). Frances A. Shepherd collaborates with scholars based in Canada, United States and United Kingdom. Frances A. Shepherd's co-authors include Ming‐Sound Tsao, Lesley Seymour, Keyue Ding, Ronald Feld, William K. Evans, Vera Hirsh, Natasha B. Leighl, Gilda da Cunha Santos, Andrea Bezjak and Gary M. Clark and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Frances A. Shepherd

649 papers receiving 48.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2005 4.3k citations Frances A. Shepherd, Tudor–Eliade Ciuleanu et al. profile →
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

2016 2.4k citations Frances A. Shepherd, Chee Khoon Lee et al. profile →
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

2004 1.9k citations Frances A. Shepherd et al. Journal of Clinical Oncology profile →
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

2008 1.8k citations Jean‐Pierre Pignon, Hélène Tribodet et al. Journal of Clinical Oncology profile →
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

2000 1.7k citations Frances A. Shepherd, Janet Dancey et al. Journal of Clinical Oncology profile →
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

2005 1.5k citations Ming‐Sound Tsao, Akira Sakurada et al. profile →
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

2008 1.0k citations Vera Hirsh, Frances A. Shepherd et al. profile →
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

2009 999 citations Frances A. Shepherd, Gail Darling et al. profile →
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

2016 700 citations Frances A. Shepherd et al. profile →
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 694 citations Frances A. Shepherd, Richard J. Gralla et al. Journal of Clinical Oncology profile →
EGFR Mutations and Lung Cancer

2011 691 citations Gilda da Cunha Santos, Frances A. Shepherd et al. profile →
Non-small-cell lung cancer

2011 584 citations Thierry Le Chevalier, Frances A. Shepherd et al. profile →
The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

2009 568 citations Giorgio V. Scagliotti, Frances A. Shepherd et al. profile →
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

2008 561 citations Chang‐Qi Zhu, Gilda da Cunha Santos et al. Journal of Clinical Oncology profile →
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

2016 502 citations Frances A. Shepherd et al. profile →
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

2016 394 citations Frances A. Shepherd et al. Journal of Clinical Oncology profile →
Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

2016 350 citations Frances A. Shepherd et al. Journal of Clinical Oncology profile →
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

2023 263 citations Terufumi Kato, Frances A. Shepherd et al. profile →
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

2017 235 citations Peter Ellis, Frances A. Shepherd et al. Journal of Clinical Oncology profile →
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

2023 95 citations James Chih‐Hsin Yang, Frances A. Shepherd et al. profile →

Peers

Countries citing papers authored by Frances A. Shepherd

Since Specialization

Citations

This map shows the geographic impact of Frances A. Shepherd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frances A. Shepherd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frances A. Shepherd more than expected).

Fields of papers citing papers by Frances A. Shepherd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frances A. Shepherd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frances A. Shepherd. The network helps show where Frances A. Shepherd may publish in the future.

Co-authorship network of co-authors of Frances A. Shepherd

This figure shows the co-authorship network connecting the top 25 collaborators of Frances A. Shepherd. A scholar is included among the top collaborators of Frances A. Shepherd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frances A. Shepherd. Frances A. Shepherd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors 2024 ·JTO Clinical and Research Reports ·(unknown), (unknown), Hans Katzberg, Vera Bril, (unknown), Warren Mason, (unknown), Aideen E. Ryan, David W. Hogg, Srikala S. Sridhar, Neesha C. Dhani, Anna Spreafico, Lawson Eng, Adrian G. Sacher, Penelope A. Bradbury, Geoffrey Liu, Natasha B. Leighl, Frances A. Shepherd	0
2	Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Final results of the investigator-initiated phase II BEAVER trial. 2024 ·Journal of Clinical Oncology ·April A. N. Rose, (unknown), (unknown), (unknown), (unknown), (unknown), Ian King, Tong Zhang, (unknown), Trevor J. Pugh, Marcus O. Butler, Frances A. Shepherd, Philippe L. Bédard, Natasha B. Leighl, Albiruni Ryan Abdul Razak, Aaron R. Hansen, Samuel D. Saibil, Lillian L. Siu, David W. Cescon, Anna Spreafico	2
3	512MO FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC 2023 ·Annals of Oncology ·David Planchard, Pasi A. Jänne, Ying Cheng, Chee Khoon Lee, К. К. Лактионов, (unknown), Yan Yu, Terufumi Kato, Lingxiang Jiang, (unknown), Sarayut Lucien Geater, (unknown), (unknown), Libor Havel, Frances A. Shepherd, Kentaro Tanaka, Dana Ghiorghiu, Edgar Monterroso, (unknown), James Chih‐Hsin Yang	0
4	The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance 2019 ·Lung Cancer ·Grainne M. O’Kane, Geoffrey Liu, Tracy Stockley, (unknown), Tong Zhang, Jennifer Law, Lisa W. Le, Adrian G. Sacher, Frances A. Shepherd, Penelope A. Bradbury, (unknown)	14
5	Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer 2019 ·Cancers ·Dennis Wang, Nhu‐An Pham, Timothy M. Freeman, Vibha Raghavan, Roya Navab, (unknown), Chang‐Qi Zhu, Dalam Ly, Jiefei Tong, Bradly G. Wouters, Melania Pintilie, Michael F. Moran, Geoffrey Liu, Frances A. Shepherd, Ming‐Sound Tsao	4
6	Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA -Mutant Lung Squamous Cell Carcinoma 2018 ·Clinical Cancer Research ·Ruoshi Shi, Ming Li, Vibha Raghavan, (unknown), Michael Cabanero, Nhu‐An Pham, Frances A. Shepherd, Nadeem Moghal, Ming‐Sound Tsao	20
7	Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung 2015 ·Clinical Cancer Research ·Maud H. W. Starmans, Melania Pintilie, Michelle Chan‐Seng‐Yue, Nathalie C. Moon, Syed Haider, Francis Nguyen, Suzanne K. Lau, Ni Liu, Arek Kasprzyk, Bradly G. Wouters, Sandy D. Der, Frances A. Shepherd, Igor Jurišica, Linda Z. Penn, Ming‐Sound Tsao, Philippe Lambin, Paul C. Boutros	10
8	NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma 2015 ·Clinical Cancer Research ·David W. Cescon, (unknown), Shingo Sakashita, Chang‐Qi Zhu, Melania Pintilie, Frances A. Shepherd, Ming‐Sound Tsao	48
9	Depression and use of health care services in patients with advanced cancer. 2013 ·PubMed ·Christopher Lo, Andrew Calzavara, Paul Kurdyak, Lisa Barbera, Frances A. Shepherd, Camilla Zimmermann, Malcolm J. Moore, Gary Rodin	20
10	Association of the 15q25 and 5p15 Lung Cancer Susceptibility Regions with Gene Expression in Lung Tumor Tissue 2012 ·Cancer Epidemiology Biomarkers & Prevention ·(unknown), Geoffrey Liu, Melania Pintilie, Jenna Sykes, Dangxiao Cheng, Ni Liu, Zhuo Chen, Lesley Seymour, Sandy D. Der, Frances A. Shepherd, Ming‐Sound Tsao, Rayjean J. Hung	14
11	L1 Cell Adhesion Molecule Promotes Tumorigenicity and Metastatic Potential in Non–Small Cell Lung Cancer 2012 ·Clinical Cancer Research ·Josephine Hai, Chang‐Qi Zhu, Bizhan Bandarchi, Yuhui Wang, Roya Navab, Frances A. Shepherd, Igor Jurišica, Ming‐Sound Tsao	49
12	Adoption of Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer: A Population-Based Outcomes Study 2010 ·Journal of Clinical Oncology ·Christopher M. Booth, Frances A. Shepherd, Yingwei Peng, Gail Darling, Gavin Li, Weidong Kong, William J. Mackillop	54
13	Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 breakdown → 2008 ·Journal of Clinical Oncology ·Chang‐Qi Zhu, Gilda da Cunha Santos, Keyue Ding, Akira Sakurada, Jean-Claude Cutz, Ni Liu, Tong Zhang, Paula Marrano, Marlo Whitehead, Jeremy A. Squire, Suzanne Kamel‐Reid, Lesley Seymour, Frances A. Shepherd, Ming‐Sound Tsao	561
14	Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non–Small-Cell Lung Cancer 2008 ·Journal of Clinical Oncology ·Martin Früh, Estelle Rolland, Jean‐Pierre Pignon, Lesley Seymour, Keyue Ding, Hélène Tribodet, Timothy Winton, Thierry Le Chevalier, Giorgio V. Scagliotti, Jean-Yves Douillard, Stephen Spiro, Frances A. Shepherd	132
15	Three-Gene Prognostic Classifier for Early-Stage Non–Small-Cell Lung Cancer 2007 ·Journal of Clinical Oncology ·Suzanne K. Lau, Paul C. Boutros, Melania Pintilie, Fiona Blackhall, Chang‐Qi Zhu, Dan Strumpf, Michael R. Johnston, Gail Darling, Shaf Keshavjee, Thomas K. Waddell, Ni Liu, Davina Lau, Linda Z. Penn, Frances A. Shepherd, Igor Jurišica, Sandy D. Der, Ming‐Sound Tsao	189
16	Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer 2007 ·Journal of Clinical Oncology ·Charles Butts, David Bodkin, Edward L. Middleman, (unknown), David H. Ellison, Yasmin Alam, Harvey Kreisman, Peter R. Graze, James F. Maher, Helen J. Ross, Peter Ellis, William McNulty, Edward J. Kaplan, (unknown), Martin R. Weber, Frances A. Shepherd	160
17	Lung cancer screening with low-dose computed tomography: Canadian experience. 2007 ·PubMed ·Heidi Roberts, Demetris Patsios, Narinder Paul, (unknown), Gordon L. Weisbrod, TaeBong Chung, Steven D. Herman, Scott Boerner, Thomas K. Waddell, Shaf Keshavjee, Gail Darling, André Pereira, (unknown), Hamid Bayanati, (unknown), Ming‐Sound Tsao, Frances A. Shepherd	40
18	A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1^st line or 2^nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial 2004 ·Journal of Clinical Oncology ·Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Ee Hong Tan, Vera Hirsh, S. Thongprasert, Andrea Bezjak, Dongping Tu, (unknown), Lesley Seymour	212
19	Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy breakdown → 2000 ·Journal of Clinical Oncology ·Frances A. Shepherd, Janet Dancey, Rodryg Ramlau, K. Mattson, Richard J. Gralla, Mark Allen O’Rourke, Nathan Levitan, Laurent Gressot, Mark Vincent, Ronald L. Burkes, Susan Coughlin, Yong Kim, J. Bérille	1717
20	Anti-IgA-mediated transfusion reactions in Canada. 1984 ·PubMed ·Carol Laschinger, Frances A. Shepherd, (unknown)	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact